Antonio S. Montecalvo - 18 Feb 2026 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Reporting relationship: Vice President, Health Policy
Issuer ticker: ORGO
Reported as of: 18 Feb 2026
Net transaction value: -$14,365
SEC form: 4
Accepted by SEC: 20 Feb 2026, 17:26:48 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ William R. Kolb, Attorney-in-Fact

Key filing fact

Antonio S. Montecalvo filed Form 4 for Organogenesis Holdings Inc. (ORGO) on 20 Feb 2026.

Key facts

This page summarizes Antonio S. Montecalvo's Form 4 filing for Organogenesis Holdings Inc. (ORGO).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Feb 2026, 17:26.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: -$14,365.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001759261 Primary reporting owner

Montecalvo Antonio S.

Relationship: Vice President, Health Policy
Address: C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON
Signature: /s/ William R. Kolb, Attorney-in-Fact
Signature date: 20 Feb 2026

This filing has been restated. Open the amended filing.

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORGO transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +40,625
Change %: +23%
Price: $0.000000
Shares after: 218,686
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1

ORGO transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +11,218
Change %: +5.1%
Price: $0.000000
Shares after: 229,904
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F2

ORGO transaction

Class A Common Stock

Tax liability

Transaction value: $14,365
Shares: -3,741
Change %: -1.6%
Price: $3.84
Shares after: 226,163
Date: 18 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ORGO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +23,162
Change %
Price: $0.000000
Shares after: 23,162
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 23,162
Exercise price: $3.84
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026.

Footnote F2

Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones.

Footnote F3

The option becomes exercisable in equal annual installments over four years beginning February 15, 2026.